Global Digital Diabetes Management Market Size study & Forecast, by Type (Handheld Devices, Wearable Devices), by Product (Continuous blood glucose monitoring systems, Smart glucose meter, Smart insulin pumps, Smart insulin pens, Apps) and Regional Analys

Global Digital Diabetes Management Market Size study & Forecast, by Type (Handheld Devices, Wearable Devices), by Product (Continuous blood glucose monitoring systems, Smart glucose meter, Smart insulin pumps, Smart insulin pens, Apps) and Regional Analysis, 2023-2030

Global Digital Diabetes Management Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Digital diabetes management refers to using digital technologies, such as mobile apps, wearable devices, and other digital tools, to help individuals with diabetes monitor, manage, and improve their condition. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels due to either inadequate insulin production or the body's inability to use insulin effectively. Digital diabetes management solutions aim to empower patients with diabetes to take an active role in their self-care by providing tools and resources to track and analyze their blood glucose levels, medication, physical activity, and diet. The key factors driving the market growth are the rising prevalence of diabetes, growing adoption of cloud-based enterprise solutions for diabetes management, the advent of artificial intelligence in diabetes care devices, and increasing penetration of digital platforms and adoption of mobile apps for diabetes management that anticipated to support the market growth during forecast period.

Moreover, the global prevalence of diabetes has been increasing steadily, primarily due to sedentary lifestyles, unhealthy diets, and an aging population. As the number of people with diabetes continues to rise, there is a growing need for efficient and scalable diabetes management solutions. For instance, as per the International Diabetic Federation (IDF), in 2019, there were nearly 463 million adults aged between 20-79 years were suffering from diabetes. Also, the amount is anticipated to reach around 700 million by 2045. As a result, the growing prevalence of diabetes is anticipated to support market growth. Additionally, increasing diabetes-related health expenditure and rising adoption of e-health are anticipated to create a lucrative opportunity for the market during the forecast period. However, the low adoption in developing economies and data security stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Digital Diabetes Management Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising prevalence of diabetes, increasing awareness and patient engagement, growing healthcare and infrastructure, increasing focus on remote patient monitoring, and supportive reimbursement policies. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the growing adoption of e-health, increasing prevalence of diabetes, rising healthcare awareness, increasing healthcare expenditure, and growing adoption of telemedicine and remote monitoring.

Major market player included in this report are:
F. Hoffmann-La Roche Ltd.
Becton, Dickinson And Company
Bayer Ag
Acon Laboratories, Inc.
Medtronic Plc
Novo Nordisk A/S
Terumo Corporation
Abbott Laboratories
Johnson And Johnson Limited
Dexcom, Inc

Recent Developments in the Market:
 In September 2020, Roche Diagnostics (Switzerland) introduced a remote patient monitoring solution, that is an innovation of the RocheDiabetes Care Platform that utilises its pattern detection feature. These product launch helps to expand company product portfolio globally.

Global Digital Diabetes Management Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered – Type, Product, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type:
Handheld Devices
Wearable Devices

By Product:
Continuous blood glucose monitoring systems
Smart glucose meter
Smart insulin pumps
Smart insulin pens
Apps

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
F. Hoffmann-La Roche Ltd.
Becton, Dickinson And Company
Bayer Ag
Acon Laboratories, Inc.
Medtronic Plc
Novo Nordisk A/S
Terumo Corporation
Abbott Laboratories
Johnson And Johnson Limited
Dexcom, Inc

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.